Fig. 1

Anti-S protein antibodies titers by treatment groups before and after a third dose of mRNA-based SARS-CoV-2 vaccine. The circle-shaped dots show the levels of anti-S protein antibodies of the patients' baseline and follow-up samples. The diamond-shaped points and the adjacent segments display the adjusted group means of the titer values and their corresponding 95% confidence intervals, respectively. Dot colors indicate the patients’ disease condition. Adjusted means were derived from a mixed-effects linear model where sex, age, rheumatic condition, treatment type, use of glucocorticoids, type of vaccine, sample type (pre- or post-third dose) and time from previous dose where included as fixed effects, as well as the interaction between: sex and sample type; treatment and sample type; rheumatic condition and sample type; use of glucocorticoids and sample type; time from second and third vaccine dose and sample type; glucocorticoids use and treatment regimen; and glucorticoids use and rheumatic condition. Individual effects were included as random effects in this model. The y-axis is in log2-scale, while the value labels are displayed in the original scale of the titer values (BAU/ml). The horizontal dotted line indicates a value of 260 BAU/ml, which is typically used as a threshold to define a positive response to the vaccine. SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis, B27-AS HLA-B27 positive Ankylosing Spondylitis, PSA Psoriatic Arthritis, GCA Giant Cell Arteritis, GCs Glucocorticoids; JAKi JAK inhibitors